tbuckley/cabot-search huggingface dataset:
Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program
Authors: M. Maio, P. Queirolo, A. Testori, M. Altomonte, M. Maur, E. Bajetta, P.A. Ascierto, V. Chiarion Sileni, A.M. Di Giacomo, R. Ridolfi
Journal: Annals of Oncology (2012)
Randomized Phase II Trial of Zoledronic Acid in Combination with Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (NSCLC) Patients with Bone Metastases: WJTOG3806
Authors: H. Okada, H. Murakami, T. Yamanaka, T. Seto, K. Sugio, I. Okamoto, T. Sawa, T. Hirashima, S. Nakamura, M. Fukuoka, Y. Nakanishi, K. Nakagawa, N. Yamamoto
Journal: Annals of Oncology (2012)
Results of the Second Pilot External Quality Assurance Scheme for Somatic Egfr Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC)
Authors: N. Normanno, S. Patton, F.H. Blackhall, S. Murray, K. Kerr, M. Dietel, M. Filipits, S. Benlloch, R.A. Stahel, E. Thunnissen
Journal: Annals of Oncology (2012)
Do the Well-Known Risk Factors of Breast Cancer Have the Same Impact on Development of Molecular Subtypes?
Authors: F. Paksoy Türköz, M. Solak, O. Keskin, Z. Arık, F.S. Sarıcı, H. Petekkaya, T. Babacan, K.M. Altunda
Journal: Annals of Oncology (2012)
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial with VEGFR2-EPITOPE Peptide and Gemcitabine for Patients with Locally Advanced, Metastatic, or Unresectable Pancreatic Cancer: Pegasus-PC Study
Authors: H. Yamaue, M. Miyazawa, N. Mizuno, T. Okusaka, A. Fukutomi, H. Ishii, S. Ohkawa, M. Furukawa, H. Maguchi, M. Ikeda, K. Nishio, Y. Ohashi, T. Tsunoda
Journal: Annals of Oncology (2012)
Outcome and Molecular Characteristics of Young Adult Patients with Newly Diagnosed Primary Glioblastoma: A Study of the Society of Austrian Neurooncology (SANO)
Authors: C. Marosi, A. Leibetseder, M. Ackerl, B. Flechl, C. Sax, A. Wöhrer, M. Preusser, K. Dieckmann, J. Pichler, S. Spiegl Kreinecker
Journal: Annals of Oncology (2012)
Final Results of a French Sarcoma Group (FSG) Retrospective Review of 110 Patients with Primary Localized Gastrointestinal Stromal Tumors (GIST) of the Duodenum
Authors: F. Duffaud, T. Huynh, P. Cassier, E. Boucher, O. Bouché, A. Le Cesne, B. Landi, J. Mancini, F. Marchal, J. Blay
Journal: Annals of Oncology (2012)
Erratum to “Intensive care management of influenza-associated pulmonary aspergillosis” [Clin microbiol infect 25 (12) (2019) 1501–1509]
Authors: P. Koehler, M. Bassetti, M. Kochanek, A. Shimabukuro-Vornhagen, O.A. Cornely
Journal: Clinical Microbiology and Infection (2020)
The dimension and morphology of alveolar bone at maxillary anterior teeth in periodontitis: a retrospective analysis—using CBCT
Authors: Xue Zhang, Yuchao Li, Ziming Ge, Haijiao Zhao, Lei Miao, Yaping Pan
Journal: International Journal of Oral Science (2020)

Abstract The morphology of the alveolar bone at the maxillary anterior teeth in periodontitis patients was evaluated by cone-beam computed tomography (CBCT) to investigate the distribution of alveolar defects and provide guidance for clinical practice. Ninety periodontitis patients and 30 periodontally healthy individuals were selected to determine the morphology of the alveolar bone at the maxillary anterior teeth according to the degree of bone loss, tooth type, sex and age. The differences in the dimensions between periodontitis patients and healthy individuals were compared, and the distribution of alveolar bone defects was analyzed. A classification system was established regarding the sagittal positions and angulations of the teeth. The buccal residual bone was thicker and the lingual bone was thinner in the periodontitis patients than in the periodontally healthy individuals, and there were differences between the different tooth types, sexes and age subgroups. The buccal undercut was close to the alveolar ridge, while fenestration was reduced and the apical bone height was higher in periodontitis patients than in periodontally healthy individuals. The apical bone height increased with the aggravation of bone loss and age. The proportions of different sagittal positions changed with the aggravation of bone loss. Moreover, the teeth moved more buccally regarding the positions of the maxillary anterior teeth. The morphology of the alveolar bone at the maxillary anterior teeth differed between periodontitis patients and healthy individuals, and the differences were related to the degree of bone loss, tooth type, sex and age.
P-0159 Measurement of C-Kit Protein Serum Levels As A Reliable Biomarker in Diagnosis of Gastrointestinal Stromal Tumors (Gist)
Authors: Vasiliki Kakavetsi-Dimaki, Periklis Apostolopoulos, Andreas Karameris, Andreas Dimakis, Athanasios Karamountzos, Erasmia Vlachou, Panagiotis Dogatzis, Adam Adamopoulos, Irene Zoumboulis-Vafiadis, Georgios Alexandrakis, Spyridon Ladas
Journal: Annals of Oncology (2012)
Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity
Authors: El-Sayed Khafagy, Noriyasu Kamei, Yui Fujiwara, Haruka Okumura, Teruyo Yuasa, Masahiro Kato, Kenji Arime, Anna Nonomura, Hideyuki Ogino, Serena Hirano, Sayaka Sugano, Mariko Takeda-Morishita
Journal: Journal of Controlled Release (2020)
Detection of Donor’s HIV Strain in HIV-Positive Kidney-Transplant Recipient
Authors: Maria Blasi, Hannah Stadtler, Jerry Chang, Marion Hemmersbach-Miller, Christina Wyatt, Paul Klotman, Feng Gao, Cameron Wolfe, Mary Klotman
Journal: New England Journal of Medicine (2020)

HIV Transfer in Renal Transplantation despite ART In this case report, a low level of human immunodeficiency virus was shown to be transferred during transplantation of a kidney from an HIV-positiv...
Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: An Open, Non-Randomized, Multicenter Phase II Clinical Trial
Authors: S. Cai, W. Zhang, W. Li, Y. Xu, W. Gu, Z. Guan, J. Cai, C. Song, J. Xu, P. Chi
Journal: Annals of Oncology (2012)
Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis
Authors: Miguel Angel Martinez-Garcia, Rosa Faner, Grace Oscullo, David de la Rosa, Juan-Jose Soler-Cataluña, Marta Ballester, Alvar Agusti
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids (ICS) is controversial, because it can reduce the risk of future exacerbations of the disease at the expense of increasing the risk of pneumonia.Objectives: To assess the relationship between the presence of chronic bronchial infection (CBI), reduced number of circulating eosinophils, ICS treatment, and the risk of pneumonia in patients with COPD.Methods: This was a post hoc long-term observational study of an historical cohort of 201 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease II-IV) who were carefully characterized (including airway microbiology) and followed for a median of 84 months. Results were analyzed by multivariate Cox regression and network analysis.Measurements and Main Results: Mean age was 70.3 years, 90.5% of patients were male, mean FEV1 was 49%, 71.6% of patients were treated with ICS, 57.2% of them had bronchiectasis, and 20.9% had <100 blood eosinophils/μl. Pathogenic microorganisms were isolated in 42.3% of patients, and 22.4% of patients fulfilled the definition of CBI. During follow-up, 38.8% of patients suffered one or more episodes of pneumonia, with CBI (hazard ratio [HR], 1.635) and <100 eosinophils/μl (HR, 1.975) being independently associated with the risk of pneumonia, particularly when both coexist (HR, 3.126). ICS treatment increased the risk of pneumonia in those patients with <100 eosinophils/μl and CBI (HR, 2.925).Conclusions: Less than 100 circulating eosinophils/μl combined with the presence of CBI increase the risk of pneumonia in patients with COPD treated with ICS.
P-0063 Clinical Features and Outcomes of the Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation
Authors: In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Se Hoon Park, Jung Hun Kang, Gyeong Won Lee, Sung Yong Oh, Hyuck-Chan Kwon, Do Hyoung Lim, Soon Il Lee
Journal: Annals of Oncology (2012)
Opportunities in online education: Lessons learned from 250 e-lectures.
Authors: Dominik Berthold, Francesca Marangoni, Chatrina Melcher, Alberto Costa
Journal: Journal of Clinical Oncology (2013)

e17545 Background: Continuous medical education (CME) is critical for physicians, particularly in oncology because of the rapid evolution in diagnosis and treatment of malignancies. Since the fast diffusion of the internet in highly developed as well as less developed nations, online education has become a media to reach potentially a significant number of physicians around the globe. Methods: The European School of Oncology is a non-profit organization dedicated to medical education in oncology. A structured e-learning program was launched in 2008. Interactive live lectures are held by recognized experts in the field and are actively moderated. A tailored webpage www.e-eso.net has been developed. Presenters and participants are connected from their own institutes, often in distant locations. Two formats have been developed: E-grandrounds are weekly sessions on hot-topics without commercial sponsorship. E-oncoreviews are monthly sessions designed to offer a balance and comprehensive overview on a specific topic. Participants can register for free and obtain CME accreditation. Users of the live sessions are encouraged to ask questions by email. Presentations are available online for 6 months. Applications for handheld devices have been developed. Results: Between 2008 and 2012, 4700 users from 117 nations have been registered, using the application at least once. 252 online lectures were held, generating 22.000 views (about 87 participants/presentation). The cost per session was about 4000 $US ( 45$/participant) for technical support. About 100 new users per months are currently registered. None of the presenters or participants had to travel. Conclusions: This is to our knowledge the largest online education program based on non-commercial sponsorship. Online education is feasible, potentially cost-effective and ecologically sustainable. Online education is a way to equal access to medical information for economically less favored nations.
Abstract 16466: EXPLORER-HCM: Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Authors: Iacopo Olivotto, Carolyn Ho, Daniel Jacoby, Steven Lester, Matthew Roe, Andrew Wang, Jean-Francois Tamby, Joseph Lambing, June Lee, David Zhang, Amy Sehnert, Stephen Heitner
Journal: Circulation (2018)

Introduction: Hypertrophic cardiomyopathy, carries substantial lifelong morbidity, often associated with dynamic left ventricular outflow tract (LVOT) obstruction (oHCM). Since its original descrip...
P-0183 Outcomes of Patients With Colorectal Cancer With Peritoneal Carcinomatosis Who Underwent Cytoreductive Surgery and Intraperitoneal Chemotherpy Versus Palliative Chemotherapy
Authors: Dawn Chong, C.K. Tham, Iain Tan, K.C. Soo, Melissa Teo, S.P. Choo
Journal: Annals of Oncology (2012)
Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9
Authors: Jiahui Wu, Oliver H. Bell, David A. Copland, Alison Young, John R. Pooley, Ryea Maswood, Rachel S. Evans, Peng Tee Khaw, Robin R. Ali, Andrew D. Dick, Colin J. Chu
Journal: Molecular Therapy (2020)

Glaucoma is a common cause of blindness, yet current therapeutic options are imperfect. Clinical trials have invariably shown that reduction in intraocular pressure (IOP) regardless of disease subtype prevents visual loss. Reducing ciliary body aqueous humor production can lower IOP, and the adeno-associated virus ShH10 serotype was identified as able to transduce mouse ciliary body epithelium following intravitreal injection. Using ShH10 to deliver a single vector CRISPR-Cas9 system disrupting Aquaporin 1 resulted in reduced IOP in treated eyes (10.4 ± 2.4 mmHg) compared with control (13.2 ± 2.0 mmHg) or non-injected eyes (13.1 ± 2.8 mmHg; p < 0.001; n = 12). Editing in the aquaporin 1 gene could be detected in ciliary body, and no off-target increases in corneal or retinal thickness were identified. In experimental mouse models of corticosteroid and microbead-induced ocular hypertension, IOP could be reduced to prevent ganglion cell loss (32 ± 4 /mm2) compared with untreated eyes (25 ± 5/mm2; p < 0.01). ShH10 could transduce human ciliary body from post-mortem donor eyes in ex vivo culture with indel formation detectable in the Aquaporin 1 locus. Clinical translation of this approach to patients with glaucoma may permit long-term reduction of IOP following a single injection.
奇異性低流量低圧較差重症大動脈弁狭窄症患者における高圧較差への転換の予後的影響 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Yamashita Eiji, Takeuchi Masaaki, Seo Yoshihiro, Izumo Masaki, Ishizu Tomoko, Sato Kimi, Suzuki Kengo, Akashi Yoshihiro, Aonuma Kazutaka, Otsuji Yutaka, Oshima Shigeru
Journal: Circulation (2014)
Time to Progression and Safety Results of a Nonspecific Cytochrome-P 17 Inhibitor after Response/Stabilization to Docetaxel as a Maintenance Strategy in Metastatic Castratation-Resistant Prostate Cancer
Authors: I. Gil-Bazo, E. Arevalo, A. Castillo, M.E. Zudaire, O.E. Carranza, J.P. Fusco, E. Castanon Alvarez, L. Zubiri, P. Martín, I. Gil-Aldea
Journal: Annals of Oncology (2012)
Correlation between Docetaxel-Induced Skin Toxicity and the use of Steroids and H2 Blockers: A Multi-Institution Survey
Authors: K. Kawaguchi, H. Ishiguro, S. Morita, S. Nakamura, S. Ohno, N. Masuda, H. Iwata, K. Aogi, K. Kuroi, M. Toi
Journal: Annals of Oncology (2012)
Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors
Authors: A. Patnaik, K. Papadopoulos, A.W. Tolcher, M. Beeram, M. Tawashi, M. Fournel, C. Maroun, R.W. Humphrey, J. Besterman, P.J. O'Dwyer
Journal: Annals of Oncology (2012)
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
Authors: Matteo Serenelli, Alice Jackson, Pooja Dewan, Pardeep S. Jhund, Mark C. Petrie, Patrick Rossignol, Gianluca Campo, Bertram Pitt, Faiez Zannad, João Pedro Ferreira, John J.V. McMurray
Journal: JACC Heart Failure (2020)

The purpose of this study was to investigate the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes according to baseline SBP in patients with heart failure with reduced ejection fraction (HFrEF).MRAs are greatly underused in patients with HFrEF, often because of fear of adverse events. Concern about hypotension has been raised by the demonstration that MRAs are particularly effective treatment for resistant hypertension.The effect of MRA therapy was studied in 4,396 patients with HFrEF randomized in the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials.Mean SBP change from baseline to 6 months was +1.4 ± 18.1 mm Hg in the placebo group and -1.2 ± 17.9 mm Hg in the MRA group. The between-treatment difference was 2.6 mm Hg (95% confidence interval [CI]: 1.5 to 3.6; p < 0.001). All outcomes were reduced by MRA therapy overall, with consistent effects across SBP categories (e.g., all-cause mortality, overall hazard ratio [HR] of 0.72; 95% CI: 0.64 to 0.82; p < 0.001; SBP ≤105 mm Hg; HR: 0.72; 95% CI: 0.56 to 0.94; SBP >105 to ≤115 mm Hg; HR: 0.78; 95% CI: 0.60 to 1.02; SBP >115 to ≤125 mm Hg; HR: 0.71; 95% CI: 0.53 to 0.94; SBP >125 to ≤135 mm Hg; HR: 0.79; 95% CI: 0.57 to 1.10; and SBP > 135 mm Hg; HR: 0.67; 95% CI: 0.50 to 0.90; p for interaction = 0.95). Hypotension was infrequent and not more common with MRA therapy than with placebo, overall (4.6% vs. 3.9%; p = 0.25) or in any SBP category.MRA treatment had little effect on SBP in patients with HFrEF, and the clinical benefits were not modified by baseline SBP. MRA treatment infrequently caused hypotension, even when the baseline SBP was low. The treatment discontinuation rates between MRA and placebo therapy were similar. Low SBP is not a reason to withhold MRA therapy in patients with HFrEF.
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer
Authors: Neeraj Agarwal, Roberto Nussenzveig, Andrew W. Hahn, John M. Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth Boucher, Benjamin Haaland, Benjamin L. Maughan
Journal: Clinical Cancer Research (2020)

Radium-223 is approved for metastatic castration-resistant prostate cancer (mCRPC) based on improved overall survival, and delay in skeletal related events. However, it is not associated with PSA or radiographic response, which poses a challenge in real-time assessment of its efficacy. Surrogate markers of treatment outcomes may facilitate tailoring treatment duration with radium-223, by limiting the duration of therapy with radium-223 in these patients. Here, we sought to investigate the utility of bone metabolic markers (BMMs) as surrogate markers of response to radium-223 in mCRPC.A prospective phase II trial of radium-223 plus enzalutamide (RE) versus enzalutamide alone was designed to assess surrogacy of BMMs with respect to response to radium-223. Enzalutamide was used as a comparator in lieu of placebo due to the progressive disease. Co-primary endpoints were relative change in serum BMM N-telopeptide (NTP) levels from baseline to 6 months between the two arms and safety and feasibility of the combination.Thirty-nine men were randomized to RE (n = 27) or enzalutamide (n = 12). Combination was safe and feasible. Primary endpoint was met. A statistically significant relative change to NTP ratios between arms (0.64, 95% confidence interval, 0.51-0.81; P = 0.00048) favored RE versus enzalutamide. Overall, BMMs decreased with the RE therapy compared with enzalutamide. Improved PSA response rate in RE versus enzalutamide (P = 0.024), correlated with decline in BMMs.BMMs declined significantly with combination therapy, and were associated with improved outcomes. Upon external validation, BMMs may emerge as surrogate markers to monitor treatment with radium-223 in real-time.
Phase II Study Of S-1, Oral Leucovorin, Oxaliplatin and Bevacizumab Combination Therapy (SOL + BV; SOLA) in Patients with Unresectable Metastatic Colorectal Cancer (MCRC)
Authors: Y. Miyata, T. Nishina, T. Kato, K. Yamazaki, T. Yoshino, T. Esaki, T. Moriwaki, I. Hyodo
Journal: Annals of Oncology (2012)
Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle
Authors: Nancy L. Bartlett
Journal: Journal of Clinical Oncology (2020)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
エルドハイム・チェスター病の多面的臨床所見および症状: 文献と新たな10症例の包括的レビュー | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Cavalli Giulio, Guglielmi Barbara, Berti Alvise, Campochiaro Corrado, Sabbadini Maria Grazia, Dagna Lorenzo
Journal: Annals of the Rheumatic Diseases (2013)
Author Correction: Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain
Authors: Steven M. Graves, Zhong Xie, Kristen A. Stout, Enrico Zampese, Lena F. Burbulla, Jean C. Shih, Jyothisri Kondapalli, Tommaso Patriarchi, Lin Tian, Lars Brichta, Paul Greengard, Dimitri Krainc, Paul T. Schumacker, D. James Surmeier
Journal: Nature Neuroscience (2020)
Thinking about the past as the past for the past's sake: Why did temporal reasoning evolve?
Authors: Johannes B. Mahr
Journal: Behavioral and Brain Sciences (2019)

Abstract Hoerl &amp; McCormack discuss the benefits of temporal reasoning mainly with respect to future planning and decision making. I point out that, for humans, the ability to represent particular past times has distinct benefits, which are independent from contributing to future-directed cognition. Hence, the evolution of the temporal reasoning system was not necessarily driven primarily by its benefits for future-directed cognition.
P-0055 Clinical Features and Treatment of Gastric Gist - our Experience
Authors: Avdyl Krasniqi, Besnik Bicaj, Rifat Bajrami, Faton Hoxha, Agim Sharku, Astrit Hamza, Valon Zejnullahu, Fisnik Kurshumliu, Lumturije Gashi-Luci
Journal: Annals of Oncology (2012)
ASP3026, a Selective ALK Inhibitor, Induces Tumor Regression against Crizotinib Resistant EML4-ALK-Dependent Tumor Models in Mice
Authors: S. Konagai, M. Mori, I. Shimada, Y. Kondoh, N. Shindou, T. Soga, T. Furutani, H. Sakagami, Y. Ueno, N. Kaneko, R. Tanaka, H. Fushiki, R. Saito, S. Kuromitsu
Journal: Annals of Oncology (2012)
Development of a Predictive Score Using Amphiregulin (AREG), Epiregulin (EREG) and Egfr-Fish Expression Levels to Determine Treatment Efficacy in Mcrc Patients Receiving Cetuximab-Based Therapy. Analysis of the German AIO CRC-0104 Trial
Authors: V. Heinemann, R. Laubender, D.P. Modest, A. Jung, L. Fischer von Weikersthal, U. Vehling-Kaiser, C. Giessen, T. Kirchner, U. Mansmann, S. Stintzing
Journal: Annals of Oncology (2012)
A Phase I Trial of Bortezomib in Combination with Epirubicin, Carboplatin and Capecitabine (ECARBOX) in advanced Gastric and Gastro-Oesophageal Junction (GOJ) Adenocarcinoma
Authors: R.C. Turkington, C. Purcell, R.H. Wilson, M.M. Eatock
Journal: Annals of Oncology (2012)
The HENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma
Authors: M. Raponi, J. Isaacson, H. Hahn, M. Bartosiewicz, A. Magnusson, K. Lin, L. Rolfe, A. Allen, V. Picozzi
Journal: Annals of Oncology (2012)
Digital twins to personalize medicine
Authors: Bergthor Björnsson, Carl Borrebaeck, Nils Elander, Thomas Gasslander, Danuta R. Gawel, Mika Gustafsson, Rebecka Jörnsten, Eun Jung Lee, Xinxiu Li, Sandra Lilja, David Martínez-Enguita, Andreas Matussek, Per Sandström, Samuel Schäfer, Margaretha Stenmarker, X. F. Sun, Oleg Sysoev, Huan Zhang, Mikael Benson
Journal: Genome Medicine (2019)

Personalized medicine requires the integration and processing of vast amounts of data. Here, we propose a solution to this challenge that is based on constructing Digital Twins. These are high-resolution models of individual patients that are computationally treated with thousands of drugs to find the drug that is optimal for the patient.
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (TC) Versus Paclitaxel Plus Cisplatin (TP) in Stage IVB or Recurrent Cervical Cancer: Japan Clinical Oncology Group Study (JCOG0505)
Authors: R. Kitagawa, N. Katsumata, T. Shibata, T. Nakanishi, S. Nishimura, S. Nishio, M. Takano, T. Satoh, H. Yokota, K. Ochiai, J. Kigawa, H. Kobayashi, K. Kanato, H. Yoshikawa, T. Kamura
Journal: Annals of Oncology (2012)